Terms: = Thyroid cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Prognosis
73 results:
1. IFI30 as a key regulator of pdl1 immunotherapy prognosis in breast cancer.
Li L; Fei Y; Dong T; Song Y; Chen X; Zhang H; Zhou H; Liang M; Tang J
Int Immunopharmacol; 2024 May; 133():112093. PubMed ID: 38669947
[TBL] [Abstract] [Full Text] [Related]
2. Integrative analysis based on the cell cycle-related genes identifies TPX2 as a novel prognostic biomarker associated with tumor immunity in breast cancer.
Liu X; Wang W; Chen B; Wang S
Aging (Albany NY); 2024 Apr; 16(8):7188-7216. PubMed ID: 38643462
[TBL] [Abstract] [Full Text] [Related]
3. Chronic Lymphocytic thyroiditis with Oncocytic Metaplasia Influences pd-l1 Expression in Papillary thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
4. K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
Wang X; Deng X; Hu J; Zheng W; Ye D; Zhou X; Fang L
Cancer Lett; 2024 Apr; 588():216764. PubMed ID: 38431034
[TBL] [Abstract] [Full Text] [Related]
5. Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.
Li P; Wang S; Wan H; Huang Y; Yin K; Sun K; Jin H; Wang Z
Front Immunol; 2024; 15():1258475. PubMed ID: 38352883
[TBL] [Abstract] [Full Text] [Related]
6. Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.
Wang J; Ma Y; Lin H; Wang J; Cao B
BMC Immunol; 2024 Jan; 25(1):8. PubMed ID: 38267897
[TBL] [Abstract] [Full Text] [Related]
7. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
8. Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.
Ni Z; Cong S; Li H; Liu J; Zhang Q; Wei C; Pan G; He H; Liu W; Mao A
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):255-269. PubMed ID: 38186223
[TBL] [Abstract] [Full Text] [Related]
9. pd-l1 Expression and Ultrasound Characteristics in Papillary thyroid Carcinoma and Its Effect on Recurrence.
Li R; Li M; Sun B; Qi M; Peng C; Li H; Zheng S; Liu Q; Jiang C
In Vivo; 2023; 37(6):2820-2828. PubMed ID: 37905619
[TBL] [Abstract] [Full Text] [Related]
10. Network Pharmacological Analysis and Experimental Validation of the Effects of Silybin on Proliferation, Migration, and Immunotherapy of Papillary thyroid cancer.
Xie W; Li H; Lin Q; Ke N
Endocr Metab Immune Disord Drug Targets; 2024; 24(6):672-690. PubMed ID: 37855349
[TBL] [Abstract] [Full Text] [Related]
11. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting pd-l1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract] [Full Text] [Related]
12. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Guo H; Hu Z; Yang X; Yuan Z; Gao Y; Chen J; Xie L; Chen C; Guo Y; Bai Y
Int Immunopharmacol; 2023 Oct; 123():110709. PubMed ID: 37515849
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and Pathological Characteristics and prognosis of Lung Adenocarcinoma With High-Grade Fetal Features: A Retrospective Analysis.
Gu Y; Zhang S; Liang X; Zhao H; Li X; Lu J
Int J Surg Pathol; 2024 Jun; 32(4):667-678. PubMed ID: 37488988
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological and prognostic significance of pd-l1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study.
Wusiman D; Guo L; Li L; Zhang X; Zhao X; An Z; Huang Z; Zhang Y; Li Z; Ying J; Wei M; Li W; An C
J Endocrinol Invest; 2024 Jan; 47(1):91-100. PubMed ID: 37464189
[TBL] [Abstract] [Full Text] [Related]
15. PTPRC promoted CD8+ T cell mediated tumor immunity and drug sensitivity in breast cancer: based on pan-cancer analysis and artificial intelligence modeling of immunogenic cell death-based drug sensitivity stratification.
Li P; Wang W; Wang S; Cao G; Pan T; Huang Y; Wan H; Zhang W; Huang Y; Jin H; Wang Z
Front Immunol; 2023; 14():1145481. PubMed ID: 37388747
[TBL] [Abstract] [Full Text] [Related]
16. A meta-analysis of application of PD-1/pd-l1 inhibitor-based immunotherapy in unresectable locally advanced triple-negative breast cancer.
Zhang W; He Y; Tang Y; Dai W; Si Y; Mao F; Xu J; Yu C; Sun X
Immunotherapy; 2023 Sep; 15(13):1073-1088. PubMed ID: 37337734
[TBL] [Abstract] [Full Text] [Related]
17. A novel immune score model predicting the prognosis and immunotherapy response of breast cancer.
Lv W; He X; Wang Y; Zhao C; Dong M; Wu Y; Zhang Q
Sci Rep; 2023 Apr; 13(1):6403. PubMed ID: 37076508
[TBL] [Abstract] [Full Text] [Related]
18. pd-l1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
19. Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer.
Su Y; Xu B; Li J; Shen Q; Lei Z; Ma M; Zhang F; Hu T
Ann Med; 2023 Dec; 55(1):1298-1316. PubMed ID: 36974635
[TBL] [Abstract] [Full Text] [Related]
20. Synergic Induction of Autophagic Cell Death in Anaplastic thyroid Carcinoma.
Wächter S; Knauff F; Roth S; Keber C; Holzer K; Manoharan J; Maurer E; Bartsch DK; Di Fazio P
Cancer Invest; 2023 Apr; 41(4):405-421. PubMed ID: 36811581
[TBL] [Abstract] [Full Text] [Related]
[Next]